Literature DB >> 6932997

Second malignancy in patients treated by Hodgkin's disease.

M Baccarani, A Bosi, G Papa.   

Abstract

Six hundred and thirteen consecutive patients with Hodgkin's disease (HD), with a follow-up of two to ten years, were reviewed with the aim of establishing the type and frequency of second malignancies. Acute non-lymphoid leukemia developed in 2 of 152 patients treated by chemotherapy (CHT), and in 5 of 344 patients treated by CHT and radiotherapy (RT). Leukemia developed 12 to 83 months after diagnosis of HD, was always preceded by a preleukemic phase (3 to 25 months), and was always fatal (after 1 to 12 months). The karyotype of leukemic cells was studied in 4 of 7 patients and was always abnormal. Solid tumors developed in 1 of 152 patients treated by CHT, and in 4 of 344 patients treated by CHT and RT. The tumors appeared 10 to 63 months after diagnosis of HD and killed all 5 patients after 10 to 16 months. For patients treated by CHT, the actuarial frequency of leukemia and other tumors seven years after diagnosis of HD was 2.0% and 1.26%, respectively. For patients treated by CHT and RT, the figures were 2.04% and 2.26%, respectively. Second malignancies were not recorded among 117 patients treated by RT alone. These data are consistent with a relationship of acute leukemia to therapy for HD.

Entities:  

Mesh:

Substances:

Year:  1980        PMID: 6932997     DOI: 10.1002/1097-0142(19801015)46:8<1735::aid-cncr2820460806>3.0.co;2-3

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  12 in total

1.  Increased risk of second cancers in managing Hodgkins disease: the 20-year Leiden experience.

Authors:  J K Sont; W A van Stiphout; E M Noordijk; J Molenaar; J H Zwetsloot-Schonk; R Willemze; J P Vandenbroucke
Journal:  Ann Hematol       Date:  1992-11       Impact factor: 3.673

2.  Leukaemia complicating treatment for Hodgkin's disease: the experience of the British National Lymphoma Investigation.

Authors:  S Devereux; T G Selassie; G Vaughan Hudson; B Vaughan Hudson; D C Linch
Journal:  BMJ       Date:  1990-11-10

3.  Malignant lymphoma of the conjunctiva following Hodgkin's disease.

Authors:  H E Grossniklaus; D C Farhi; B R Jacobson; M F Abbuhl
Journal:  Br J Ophthalmol       Date:  1988-03       Impact factor: 4.638

4.  Case report 409: Non-Hodgkin lymphoma (diffuse histiocytic or malignant lymphoma, diffuse, large cell B-cell immunophenotype).

Authors:  T S Samuels; B A Howard; J D Rubenstein; J Srigley
Journal:  Skeletal Radiol       Date:  1987       Impact factor: 2.199

5.  Treatment of therapy-induced preleukemic syndrome.

Authors:  M Gyger; C Perreault; J Carnot; J Boileau; Y Bonny
Journal:  Blut       Date:  1984-02

6.  Composite lymphoma: a case report.

Authors:  J Coyne; P Dervan
Journal:  Ir J Med Sci       Date:  1984-02       Impact factor: 1.568

7.  Soft tissue sarcoma as second malignant lesion after therapy for Hodgkin's disease. Report of two cases and review of the literature.

Authors:  G H Griesser; M L Hansmann
Journal:  J Cancer Res Clin Oncol       Date:  1985       Impact factor: 4.553

8.  Lung cancer following therapy for Hodgkin's disease.

Authors:  L Oliphant; R G McFadden
Journal:  Can Med Assoc J       Date:  1985-03-01       Impact factor: 8.262

9.  Monomorphic lymphomas arising in patients with Hodgkin's disease. Correlation of morphologic, immunophenotypic, and molecular genetic findings in 12 cases.

Authors:  T T Casey; J B Cousar; M Mangum; M E Williams; J T Lee; J P Greer; R D Collins
Journal:  Am J Pathol       Date:  1990-01       Impact factor: 4.307

10.  Prognostic factors in COPP-treated patients with Hodgkin's disease.

Authors:  W Gassmann; L Perenyi; N Schmitz; W Kayser; H Pralle; H Löffler
Journal:  Blut       Date:  1982-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.